Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Immunis
Deal Size : Undisclosed
Deal Type : Partnership
Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia
Details : The partnership aims to focus on the clinical development of TRK-820 (nalfurafine hydrochloride), which is being evaluated for the treatment of Uremic Pruritus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 22, 2024
Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Immunis
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus
Details : TRK-820 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pruritus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 23, 2016
Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
